Drug Approval | September 10, 2025
Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
New unit boosts innovation in liposomal delivery technologies with 8,500 MT capacity and export-ready production
Accelerating RNA-based therapeutic solutions for customers through co-development of products and formulation support
The cGMP-4 facility will further strengthen the company's ability to serve global partners
Funding to support Phase 2b trial with MRM Health’s lead program MH002 in ulcerative colitis and advance two additional programs to IND approval
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Agreement further expands Aptar Pharma’s leading position in nasal delivery solutions and addresses significant unmet needs of delivering drugs locally over extended periods
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Subscribe To Our Newsletter & Stay Updated
